Hims & Hers Reports Q1 Net Loss and Lower EBITDA, Raises Full-Year Revenue Guidance Amid GLP-1 Pivot

summarizeSummary

Hims & Hers Health reported a Q1 net loss and lower Adjusted EBITDA, but raised its full-year revenue guidance, emphasizing its strategic pivot into branded GLP-1 products.

check_boxKey Events

• Q1 2026 Financial Performance

  The company reported Q1 2026 revenue of $608.1 million, a 4% increase year-over-year. However, it swung to a net loss of $92.1 million from a net income of $49.5 million in Q1 2025, and Adjusted EBITDA declined significantly to $44.3 million from $91.1 million.

• Full-Year 2026 Guidance Raised for Revenue

  Hims & Hers raised its full-year 2026 revenue guidance to a range of $2.8 billion to $3.0 billion. Full-year Adjusted EBITDA guidance was updated to a range of $275 million to $350 million.

• Strategic Pivot to Branded GLP-1 Products

  Management highlighted a strategic pivot to expand its assortment of branded GLP-1 products, noting early demand signals show meaningful consumer reach broadening. This follows recent news and an 8-K filing on March 11, 2026, regarding a collaboration with Novo Nordisk.

• Subscriber Growth Continues

  Subscribers grew to nearly 2.6 million in Q1 2026, representing a 9% increase year-over-year, indicating continued customer acquisition despite profitability challenges.

auto_awesomeAnalysis

Hims & Hers Health reported a significant shift to a net loss and a substantial decline in Adjusted EBITDA for Q1 2026 compared to the prior year. This profitability hit is a key concern for investors. However, the company simultaneously raised its full-year revenue guidance, projecting accelerated growth, and highlighted its strategic expansion into branded GLP-1 products. This indicates a trade-off where current profitability is impacted by investments and strategic shifts, but management expects stronger top-line growth in the future, particularly from the high-demand GLP-1 market. Investors will be weighing the immediate profitability challenges against the positive revenue outlook and strategic direction.